You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Market Movers

Eye drug could face generic rivals sooner

Allergan makes Restasis to treat chronic dry eye.

AFP

Allergan makes Restasis to treat chronic dry eye.

Continue reading below

Allergan Inc.’s Restasis treatment for chronic dry eye disease could face generic competition sooner than expected, leading to downgrades by Deutsche Bank and Leerink Swann, Dow Jones reported. Sales estimates for Restasis, Allergan’s second-biggest drug, could be reduced 67 percent in 2016, Deutsche Bank said; it cut its rating to “hold.” Analysts assumed “minimal to no generic risk” for Allergan, which also makes Botox, but new FDA guidance changes the equation, the investment bank said.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com